316 related articles for article (PubMed ID: 34011627)
1. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.
Garris CS; Wong JL; Ravetch JV; Knorr DA
Sci Transl Med; 2021 May; 13(594):. PubMed ID: 34011627
[TBL] [Abstract][Full Text] [Related]
2. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
[TBL] [Abstract][Full Text] [Related]
3. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Wong JL; Smith P; Angulo-Lozano J; Ranti D; Bochner BH; Sfakianos JP; Horowitz A; Ravetch JV; Knorr DA
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2306782120. PubMed ID: 37607227
[TBL] [Abstract][Full Text] [Related]
4. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Wong JL; Smith P; Angulo-Lozano J; Ranti D; Bochner BH; Sfakianos JP; Horowitz A; Ravetch JV; Knorr DA
bioRxiv; 2023 Feb; ():. PubMed ID: 36778311
[TBL] [Abstract][Full Text] [Related]
5. Intravesical oncolytic virotherapy and immunotherapy for non-muscle-invasive bladder cancer mouse model.
Smelser WW; Wang J; Ogden KM; Chang SS; Kirschner AN
BJU Int; 2023 Sep; 132(3):298-306. PubMed ID: 36961272
[TBL] [Abstract][Full Text] [Related]
6. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
Huang KC; Chanda D; McGrath S; Dixit V; Zhang C; Wu J; Tendyke K; Yao H; Hukkanen R; Taylor N; Verbel D; Kim DS; Endo A; Noland TA; Chen Y; Matijevic M; Wang J; Hutz J; Sarwar N; Fang FG; Bao X
Mol Cancer Ther; 2022 Jun; 21(6):914-924. PubMed ID: 35313332
[TBL] [Abstract][Full Text] [Related]
8. FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer.
Zhang Y; Huo F; Cao Q; Jia R; Huang Q; Wang ZA; Theodorescu D; Lv Q; Li P; Yan C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361729
[TBL] [Abstract][Full Text] [Related]
9. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
10. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
[TBL] [Abstract][Full Text] [Related]
11. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
12. Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.
Kirschner AN; Wang J; Rajkumar-Calkins A; Neuzil KE; Chang SS
J Urol; 2021 May; 205(5):1336-1343. PubMed ID: 33356477
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guérin: A Long-Term Follow-Up Study of a Japanese Cohort.
Miyake M; Tatsumi Y; Gotoh D; Ohnishi S; Owari T; Iida K; Ohnishi K; Hori S; Morizawa Y; Itami Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Shimada K; Konishi N; Tanaka N; Fujimoto K
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29048388
[TBL] [Abstract][Full Text] [Related]
15. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
16. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
17. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
18. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
[TBL] [Abstract][Full Text] [Related]
19. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
Chaib M; Sipe LM; Yarbro JR; Bohm MS; Counts BR; Tanveer U; Pingili AK; Daria D; Marion TN; Carson JA; Thomas PG; Makowski L
Cancer Lett; 2022 Apr; 531():98-108. PubMed ID: 35074498
[TBL] [Abstract][Full Text] [Related]
20. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
